← All trials
NCT03637335
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 17, 2015
- Primary completion
- Nov 28, 2017
- Completion date
- May 28, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 26
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Institut de Cancerologie de l'Ouest Paul PapinLead sponsor
- Centre Jean BernardOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.